(2022) Therapeutic Potential of Resveratrol in Diabetic Nephropathy According to Molecular Signaling. CURRENT MOLECULAR PHARMACOLOGY. pp. 716-735. ISSN 1874-4672 1874-4702 J9 - CURR MOL PHARMACOL
Full text not available from this repository.
Abstract
Background: Diabetic nephropathy (DN), as a severe complication of diabetes mellitus (DM), is a crucial menace for human health and survival and remarkably elevates the healthcare systems' costs. Therefore, it is worth noting to identify novel preventive and therapeutic strategies to alleviate the disease conditions. Resveratrol, as a well-defined anti-diabetic/ antioxidant agent has capabilities to counteract diabetic complications. It has been predicted that resveratrol will be a fantastic natural polyphenol for diabetes therapy in the next few years. Objective: Accordingly, the current review aims to depict the role of resveratrol in the regulation of different signaling pathways that are involved in the reactive oxygen species (ROS) production, inflammatory processes, autophagy, and mitochondrial dysfunction, as critical contributors to DN pathophysiology. Results: The pathogenesis of DN can be multifactorial; hyperglycemia is one of the prominent risk factors of DN development that is closely related to oxidative stress. Resveratrol, as a well-defined polyphenol, has various biological and medicinal properties, including anti-diabetic, anti-inflammatory, and anti-oxidative effects. Conclusion: Resveratrol prevents kidney damages that are caused by oxidative stress, enhances antioxidant capacity, and attenuates the inflammatory and fibrotic responses. For this reason, resveratrol is considered an interesting target in DN research due to its therapeutic possibilities during diabetic disorders and renal protection.
Item Type: | Article |
---|---|
Keywords: | Diabetic nephropathy resveratrol signaling pathway oxidative stress inflammation cellular mechanisms NF-KAPPA-B NRF2-ARE ANTIOXIDATIVE PATHWAY ENDOPLASMIC-RETICULUM STRESS TUBULAR EPITHELIAL-CELLS INDUCED UP-REGULATION FATTY LIVER-DISEASE DOUBLE-BLIND MITOCHONDRIAL DYSFUNCTION PODOCYTE INJURY |
Page Range: | pp. 716-735 |
Journal or Publication Title: | CURRENT MOLECULAR PHARMACOLOGY |
Journal Index: | ISI |
Volume: | 15 |
Number: | 5 |
Identification Number: | https://doi.org/10.2174/1874467215666211217122523 |
ISSN: | 1874-4672 1874-4702 J9 - CURR MOL PHARMACOL |
Depositing User: | Zahra Otroj |
URI: | http://eprints.mui.ac.ir/id/eprint/15858 |
Actions (login required)
View Item |